# Abiraterone Acetate, Prednisone, and Apalutamide With or Without Ipilimumab or Cabazitaxel and Carboplatin in Treating Patients With Metastatic Castration-Resistant Prostate Cancer

> **NCT02703623** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **M.D. Anderson Cancer Center** · enrollment: 196 (actual)

## Conditions studied

- Castration Levels of Testosterone
- Castration-Resistant Prostate Carcinoma
- Metastatic Prostate Carcinoma
- PSA Progression
- Stage IV Prostate Adenocarcinoma AJCC v7

## Interventions

- **DRUG:** Abiraterone Acetate
- **DRUG:** Apalutamide
- **DRUG:** Cabazitaxel
- **DRUG:** Carboplatin
- **BIOLOGICAL:** Ipilimumab
- **OTHER:** Laboratory Biomarker Analysis
- **DRUG:** Prednisone

## Key facts

- **NCT ID:** NCT02703623
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2016-05-18
- **Primary completion:** 2028-03-31
- **Final completion:** 2028-03-31
- **Target enrollment:** 196 (ACTUAL)
- **Last updated:** 2026-03-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02703623

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02703623, "Abiraterone Acetate, Prednisone, and Apalutamide With or Without Ipilimumab or Cabazitaxel and Carboplatin in Treating Patients With Metastatic Castration-Resistant Prostate Cancer". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT02703623. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*